Obesity is associated with reduced fertility and poorer semen measures in some men. Weight loss may improve reproductive health, but the evidence is variable and assessment should not be delayed while waiting for a target weight.
Obesity is associated with reduced fertility in men and can affect hormones, sexual function and some semen measures. Weight loss may improve parts of that picture, particularly when metabolic health and obesity-related hormone suppression improve, but current evidence does not support promising that weight loss will normalise sperm or lead to pregnancy.
If conception matters now, assessment should run alongside weight management. Waiting months to reach a target weight can lose valuable time and may miss another treatable cause.
Male fertility depends on sperm production and transport, sexual function, hormones, genetics and the health of both partners. Obesity can intersect with several of these systems.
Possible pathways include:
These are biologically plausible and supported to different degrees, but they do not prove why a particular couple is having difficulty. A man with obesity can have normal semen results, while a man with a lower BMI can have a significant male-factor problem.
NICE's 2026 fertility guideline advises that men with a BMI of 30 or above have an increased risk of reduced fertility. NICE: Factors that can affect fertility
No. Population studies show associations, not a diagnosis for an individual.
Semen analysis measures characteristics such as volume, sperm concentration, total count, motility and morphology. These values naturally vary between samples and do not measure every aspect of sperm function. They also cannot predict pregnancy with certainty.
The European Association of Urology notes that obesity is associated with reduced sperm quality and lower testosterone, but also that evidence on the effect of weight loss on semen parameters is limited, non-controlled and conflicting. EAU male-infertility guideline
Assessment should identify the modifiable risks and clinical causes present now. Body weight alone cannot determine whether a man is infertile.
It may improve some reproductive measures in some men, but the evidence is not strong enough for a guarantee.
Weight reduction can improve insulin resistance, sleep apnoea, blood pressure, mobility, sexual function and obesity-related suppression of testosterone. Each of those changes can support reproductive health. Small studies have reported improvements in sperm concentration or count after lifestyle-induced weight loss, but study designs, participants and outcomes differ.
The EAU concludes that lifestyle improvement may help sperm quality and chances of conception, while specifically cautioning that weight-loss evidence is conflicting. It also reports that a meta-analysis of bariatric-surgery studies did not demonstrate improved sperm quality. EAU male-infertility guideline
Better metabolic health remains a valid objective even when semen changes are uncertain. Bariatric surgery may be the right obesity treatment for an eligible patient, but it should not be presented as a fertility intervention.
Sperm production takes roughly three months, so changes in semen cannot be assessed meaningfully from one week to the next. At the same time, fertility is a couple-level and time-sensitive issue.
Investigation should not stop while a man works on weight. Parallel care can include:
NICE recommends repeating an abnormal semen test, ideally around three months later, while allowing an earlier repeat when azoospermia or severe oligozoospermia is found. After two or more abnormal tests, men should be offered examination and considered for relevant hormone testing. NICE NG257 fertility guideline
External testosterone can make a blood testosterone result rise while sperm production falls.
Testosterone therapy and anabolic-androgenic steroids suppress luteinising hormone and follicle-stimulating hormone, reducing the signals needed for the testes to produce sperm. The effect can be severe, and recovery after stopping is variable in timing and completeness.
NICE advises clinicians to ask men and trans women with fertility concerns about testosterone replacement therapy and other medicines that may affect fertility. NICE also advises not to offer androgens to men with semen abnormalities because they do not improve fertility. NICE male-factor fertility management
Men who want children now or in future should discuss that objective before starting testosterone. A low testosterone result in this setting requires a fertility-aware endocrine or andrology pathway, not automatic replacement.
Non-prescribed anabolic steroids deserve the same open, non-judgemental discussion. The clinician needs to know what was taken, at what dose and when, because this changes the investigation and recovery plan.
Direct evidence on current weight-management medicines and male fertility is still limited. Improvements in weight and metabolic health may be beneficial, but that is not the same as demonstrating that a medicine improves sperm or pregnancy outcomes.
NICE advises asking people with fertility concerns about GLP-1 receptor agonists and other medicines and discussing their possible effects on fertility. NICE: Factors that can affect fertility
A man planning conception should tell both the fertility clinician and the medicine prescriber. He should not stop, switch or alter a prescribed weight-management medicine without advice. The decision should consider the indication, treatment benefit, current evidence, other health conditions and the couple's timeline.
Online claims that semaglutide or tirzepatide "boosts male fertility" go beyond the evidence. Where studies report hormone or sperm changes, they are often small and cannot establish the chance of conception or a live birth.
The fertility history should include prescription, non-prescription and recreational substances. Relevant examples may include:
This list does not mean every medicine causes infertility or needs to be stopped. Stopping essential treatment can be harmful. The purpose is to identify timing, dose and plausible effects, then make a supervised decision.
NICE specifically recommends asking about GLP-1 agonists, testosterone replacement, finasteride, over-the-counter medicines and recreational drugs when fertility is a concern. NICE: Factors that can affect fertility
A useful preconception plan focuses on health changes with wider benefits rather than an unproven fertility "detox".
Consider:
NICE notes that smoking is associated with reduced semen quality and that excessive alcohol is detrimental to semen quality. It also states that the effectiveness of complementary therapies for fertility has not been properly evaluated. NICE: Factors that can affect fertility
No supplement should be presented as a substitute for diagnosis. "Male fertility" products may contain overlapping nutrients, undeclared ingredients or doses that are unnecessary, and evidence for improving live-birth outcomes is limited.
Arrange fertility assessment according to the couple's circumstances, not only the man's age or weight. Earlier assessment is appropriate when there is:
The NHS advises speaking to a GP when pregnancy has not occurred after a year of regular unprotected sex, with earlier review in relevant circumstances. NHS: Low sperm count
An integrated male preconception pathway should:
At Heracles, weight management should form part of male preconception care rather than being given as a generic preliminary instruction.
Evidence for improving pregnancy or live-birth outcomes is limited. Review supplements with a clinician and do not let them delay investigation.
Bariatric surgery can improve obesity-related health, but current evidence does not reliably show improved sperm quality. Fertility timing and nutritional monitoring should be discussed with the bariatric and fertility teams.
